

Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021

<https://marketpublishers.com/r/A5C941E9D362EN.html>

Date: June 2021

Pages: 2055

Price: US\$ 2,500.00 (Single User License)

ID: A5C941E9D362EN

Abstracts

Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key

players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 23, 62, 86, 1, 4, 358, 178 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 3, 107 and 52 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor

projects.

The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Alzheimer's Disease - Overview

Alzheimer's Disease - Therapeutics Development

Alzheimer's Disease - Therapeutics Assessment

Alzheimer's Disease - Companies Involved in Therapeutics Development

Alzheimer's Disease - Drug Profiles

Alzheimer's Disease - Dormant Projects

Alzheimer's Disease - Discontinued Products

Alzheimer's Disease - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Alzheimer's Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, 2021
Alzheimer's Disease - Pipeline by 2A Pharma AB, 2021
Alzheimer's Disease - Pipeline by 4B Technologies (Suzhou) Co Ltd, 2021
Alzheimer's Disease - Pipeline by 4P-Pharma SAS, 2021
Alzheimer's Disease - Pipeline by AB Science SA, 2021
Alzheimer's Disease - Pipeline by Abaxy Spri, 2021
Alzheimer's Disease - Pipeline by AbbVie Inc, 2021
Alzheimer's Disease - Pipeline by Abrexa Pharmaceuticals Inc, 2021
Alzheimer's Disease - Pipeline by AC Immune SA, 2021
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, 2021
Alzheimer's Disease - Pipeline by Accutis Pharmaceuticals Inc, 2021
Alzheimer's Disease - Pipeline by Acelot Inc, 2021
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, 2021
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, 2021
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, 2021
Alzheimer's Disease - Pipeline by ADEL Inc, 2021
Alzheimer's Disease - Pipeline by Adocia SAS, 2021
Alzheimer's Disease - Pipeline by ADRx Inc, 2021
Alzheimer's Disease - Pipeline by Aerobyx LLC, 2021
Alzheimer's Disease - Pipeline by Aeton Therapeutics Inc, 2021
Alzheimer's Disease - Pipeline by AfaSci Inc, 2021
Alzheimer's Disease - Pipeline by AIBIOS Co Ltd, 2021
Alzheimer's Disease - Pipeline by Akome Biotech Ltd, 2021
Alzheimer's Disease - Pipeline by Alector Inc, 2021
Alzheimer's Disease - Pipeline by Alfasigma SpA, 2021
Alzheimer's Disease - Pipeline by Alkahest Inc, 2021

Alzheimer's Disease - Pipeline by Alkermes Plc, 2021
Alzheimer's Disease - Pipeline by Allyx Therapeutics Inc, 2021
Alzheimer's Disease - Pipeline by Alnylam Pharmaceuticals Inc, 2021
Alzheimer's Disease - Pipeline by AlphaCognition Inc, 2021
Alzheimer's Disease - Pipeline by Alsonex Pty Ltd, 2021
Alzheimer's Disease - Pipeline by Longeveron Inc, 2021
Alzheimer's Disease - Pipeline by LSL Neurosciences LLC, 2021
Alzheimer's Disease - Pipeline by Lyndra Therapeutics Inc., 2021
Alzheimer's Disease - Pipeline by Madera BioSciences Inc, 2021
Alzheimer's Disease - Pipeline by Magnolia Neurosciences Corp, 2021
Alzheimer's Disease - Pipeline by ManRos Therapeutics, 2021
Alzheimer's Disease - Pipeline by MapLight therapeutics Inc, 2021
Alzheimer's Disease - Pipeline by MaxiVAX SA, 2021
Alzheimer's Disease - Pipeline by MD Healthcare Inc, 2021
Alzheimer's Disease - Pipeline by MDimune Inc, 2021
Alzheimer's Disease - Pipeline by MedBiome Inc, 2021
Alzheimer's Disease - Pipeline by Medesis Pharma SA, 2021
Alzheimer's Disease - Pipeline by Medifron DBT Co Ltd, 2021
Alzheimer's Disease - Pipeline by medilabo RFP Inc, 2021
Alzheimer's Disease - Pipeline by MEDRx Co Ltd, 2021
Alzheimer's Disease - Pipeline by MegaNano BioTech Inc, 2021
Alzheimer's Disease - Pipeline by MEI Pharma Inc, 2021
Alzheimer's Disease - Pipeline by Mercia Pharma Inc, 2021
Alzheimer's Disease - Pipeline by Merck & Co Inc, 2021
Alzheimer's Disease - Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2021
Alzheimer's Disease - Pipeline by MetrioPharm AG, 2021
Alzheimer's Disease - Pipeline by MetVital Inc, 2021
Alzheimer's Disease - Pipeline by MGC Pharmaceuticals Ltd, 2021
Alzheimer's Disease - Pipeline by Mindset Pharma Inc, 2021
Alzheimer's Disease - Pipeline by Mission Therapeutics Ltd, 2021
Alzheimer's Disease - Pipeline by Mitoconix Bio Ltd, 2021
Alzheimer's Disease - Pipeline by Modag GmbH, 2021
Alzheimer's Disease - Pipeline by Montisera Ltd, 2021
Alzheimer's Disease - Pipeline by NAL Pharmaceuticals Ltd, 2021
Alzheimer's Disease - Pipeline by Nanomerics Ltd, 2021
Alzheimer's Disease - Pipeline by NatureWise Biotech & Medicals Corp, 2021
Alzheimer's Disease - Pipeline by Neonc Technologies Inc, 2021
Alzheimer's Disease - Pipeline by NeoNeuro SAS, 2021
Alzheimer's Disease - Pipeline by NeoProgen Inc, 2021

Alzheimer's Disease - Pipeline by NervGen Pharma Corp, 2021
Alzheimer's Disease - Pipeline by NeuExcell Therapeutics Inc, 2021
Alzheimer's Disease - Pipeline by Neuracle Science Co Ltd, 2021
Alzheimer's Disease - Pipeline by Neuraly Inc, 2021

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Alzheimer's Disease, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Top 10 Routes of Administration, 2021
- Number of Products by Stage and Top 10 Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/A5C941E9D362EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5C941E9D362EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970